B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study

Daniel El Fassi, Claus H Nielsen, Steen J Bonnema, Hans K Hasselbalch, Laszlo Hegedüs

    108 Citations (Scopus)

    Abstract

    Graves' disease (GD) is a common TSH receptor autoantibody (TRAb)-mediated disorder. Because B lymphocytes are important self-antigen presenting cells and precursors for antibody-secreting plasma cells, temporary B-lymphocyte depletion with the monoclonal antibody rituximab (RTX) might be of benefit in GD.
    Original languageEnglish
    JournalJournal of Clinical Endocrinology and Metabolism
    Volume92
    Issue number5
    Pages (from-to)1769-72
    Number of pages4
    ISSN0021-972X
    DOIs
    Publication statusPublished - 1 May 2007

    Fingerprint

    Dive into the research topics of 'B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study'. Together they form a unique fingerprint.

    Cite this